Regulatory Advisory: Detailed Summary of Recent CMS Interim Final Rule on COVID-19 Testing and Treatment

Rule also includes COVID-19 related changes to the Comprehensive Care for Joint Replacement Model

The Centers for Medicare & Medicaid Services (CMS) Oct. 28 announced an interim final rule establishing additional Medicare hospital payment to support Medicare beneficiaries’ access to COVID-19 vaccines and new treatments when they become available. CMS also released information on hospital billing for the outpatient administration of potential monoclonal antibody products; price transparency for COVID-19 tests; additional COVID-19 information relating to private health plans and Medicaid; and COVID-19-related changes to the Comprehensive Care for Joint Replacement (CJR) model. The rule also states that Medicare will cover any preventive vaccine at no cost to beneficiaries so long as it receives Food and Drug Administration approval via an emergency use authorization or Biologics License Application.

You must be logged in as a AHA Non-Fed Member to view the PDF file below with the full Regulatory Advisory.

Related Resources

Letter/Comment
Public
The AHA tells Senate leaders it strongly opposes “any attempt to take away previously-appropriated funding for hospitals and health systems, physicians, nurses…
Other Resources
Public
Fighting an “avoidable surge” in COVID-19 cases, the CEO and care teams at CoxHealth share stats and stories to urge their Southwest Missouri community to get…
Other Resources
Public
Photo Credit: @caitlindsutton
Other Resources
Public
AdventHealth is ramping up plans to get more people vaccinated as new variants emerge.
Action Alert
Member
AHA urges hospital and health system leaders to contact their senators and representatives and urge them not to use unobligated COVID-19 Provider Relief Funds…
Advisory
The AHA Board of Trustees today approved a policy statement that strongly urges the vaccination of all health care personnel. The AHA also supports hospitals…